Ophthotech Corp (NASDAQ:OPHT) insider David R. Guyer sold 3,798 shares of the stock in a transaction on Friday, January 5th. The shares were sold at an average price of $3.17, for a total transaction of $12,039.66. Following the sale, the insider now directly owns 42,458 shares of the company’s stock, valued at approximately $134,591.86. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Shares of Ophthotech Corp (OPHT) opened at $3.17 on Tuesday. Ophthotech Corp has a 12 month low of $2.24 and a 12 month high of $4.86. The company has a market cap of $114.24, a P/E ratio of 2.03 and a beta of 1.58.

Ophthotech (NASDAQ:OPHT) last announced its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported $5.25 EPS for the quarter, topping analysts’ consensus estimates of $4.38 by $0.87. Ophthotech had a net margin of 26.69% and a negative return on equity of 69.40%. equities analysts expect that Ophthotech Corp will post 2.88 EPS for the current fiscal year.

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Stonepine Capital Management LLC boosted its holdings in shares of Ophthotech by 1.7% in the second quarter. Stonepine Capital Management LLC now owns 3,576,189 shares of the biopharmaceutical company’s stock worth $9,155,000 after buying an additional 59,700 shares during the last quarter. Goldman Sachs Group Inc. lifted its holdings in Ophthotech by 28.1% during the second quarter. Goldman Sachs Group Inc. now owns 652,992 shares of the biopharmaceutical company’s stock valued at $1,672,000 after purchasing an additional 143,349 shares in the last quarter. First Manhattan Co. purchased a new position in Ophthotech during the third quarter valued at approximately $1,201,000. Geode Capital Management LLC lifted its holdings in Ophthotech by 3.2% during the first quarter. Geode Capital Management LLC now owns 240,571 shares of the biopharmaceutical company’s stock valued at $880,000 after purchasing an additional 7,501 shares in the last quarter. Finally, Acadian Asset Management LLC purchased a new position in Ophthotech during the fourth quarter valued at approximately $622,000. 62.06% of the stock is currently owned by institutional investors.

Several equities research analysts have recently commented on the stock. ValuEngine cut shares of Ophthotech from a “buy” rating to a “hold” rating in a research report on Sunday, December 31st. TheStreet raised shares of Ophthotech from an “e+” rating to a “c” rating in a research report on Thursday, November 30th. Finally, Zacks Investment Research upgraded shares of Ophthotech from a “hold” rating to a “strong-buy” rating and set a $3.25 price objective for the company in a research note on Monday, November 13th.

COPYRIGHT VIOLATION NOTICE: “Insider Selling: Ophthotech Corp (NASDAQ:OPHT) Insider Sells 3,798 Shares of Stock” was posted by Marea Informative and is owned by of Marea Informative. If you are viewing this article on another site, it was copied illegally and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://www.mareainformativa.com/david-r-guyer-sells-3798-shares-of-ophthotech-corp-opht-stock-updated-updated-updated/125921/.

About Ophthotech

Ophthotech Corporation is a biopharmaceutical company. The Company is engaged in the development of therapeutics to treat ophthalmic diseases, with a focus on diseases of the back of the eye. Its primary focus is developing therapeutics for age-related macular degeneration (AMD), which is a disorder of the central portion of the retina, known as the macula, that may result in blindness.

Insider Buying and Selling by Quarter for Ophthotech (NASDAQ:OPHT)

Receive News & Ratings for Ophthotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ophthotech and related companies with MarketBeat.com's FREE daily email newsletter.